Global Oral Proteins And Peptides Market Size, Growth Report 2028

Oral Proteins and Peptides Industry Prospective:

The global oral proteins and peptides market registered a revenue growth of around USD 1.24 billion in 2021 and is projected to grow with a compound annual growth rate (CAGR) of 10.4% to reach nearly USD 8.42 billion by 2028 over the forecast period. The report analyzes the oral proteins and peptides market’s drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the oral proteins and peptides market.

Request Free Sample

Oral Proteins and Peptides Market: Overview

Peptides are short sequences of amino acids that govern a variety of actions in human bodies, plants, and microbes. Insulin, which regulates sugar metabolism, and cyclosporine, which prevents organ rejection after transplantation, are two examples of peptide medicines. Peptides are a multibillion-dollar business in the pharmaceutical industry.

Previously they used to administer as injections to avoid stomach enzyme breakdown. However, scientists have devised a way of producing peptides that are resistant to enzymatic breakdown and can be consumed orally.

Request Free Sample

COVID-19 Impact:

Demand for oral protein and peptides significantly increased during the COVID-19 pandemic period. The need for peptide therapeutics to treat the COVID-19 infection primarily fueled the market demand. Peptide and protein therapeutics were considered among the major treatment options during the pandemic period. Many scientists and researchers continuously worked to test the effect of peptide therapeutics to control and treat the COVID infection. All these factors collectively upheld the market growth during the pandemic period.

Oral Proteins and Peptides Market: Growth Drivers

Increase in chronic disease around the world can boost the demand for oral proteins and peptides

The growing prevalence of chronic disease is the prime factor that is fueling the demand for global oral proteins and peptides market. According to recent statistics, approximately 15% of individuals in the United States reported having at minimum two chronic medical illnesses in 2021, compared to only around 11% of older millennials. It is the primary cause of disability and death, as well as the $3.8 trillion in annual healthcare costs in the United States.

In addition to this, the increase in the geriatric population which is prone to chronic diseases including diabetes, digestive disorders, and many more are also contributing to the market growth. Moreover, factors such as expanding healthcare infrastructure, heavy investment in drug discovery & development, and an increase in spending on healthcare are fostering the growth of the market.

Oral Proteins and Peptides Market: Restraints

High costs associated with the development and formulation of peptide therapeutics may hinder the market growth.

In addition to physiological hurdles, the formulation is a significant problem in the manufacturing of commercial oral peptides. The physical and chemical stability of peptides is the most essential concern in formulation development, intending to allow the peptide to be stable during manufacturing processes.

In solution formulation, buffer solutions are commonly used to stabilize peptides. Furthermore, various excipients, such as arginine, histidine, and glycine, are required to be included in the formulation to increase solubility or prevent protein aggregation, which adds to the process cost.

Oral Proteins and Peptides Market: Opportunities

Increasing research activities in oral peptide formulations may drive the market during the forecast period.

The global oral proteins and peptides market is rising due to increased government and private sector investment in research and development, as well as an increase in biopharmaceutical businesses throughout the world.

In addition to this, heavy investments in the launch of new therapeutic drugs for effective treatment, rise in the number of clinical trials, advancements in the technologies in drug development & research activities are also some of the additional factors that are expected to boost the market during the forecast period.

Oral Proteins and Peptides Market: Challenges

Difficulties with the metabolism and formulation of therapeutics pose a major challenge to market growth.

Peptides are a multibillion-dollar sector in the pharmaceutical industry, however, they can only be administered as injections to avoid stomach enzyme breakdown. Even though oral delivery of peptides has piqued the interest of pharmaceutical firms and research agencies, several factors hinder the progress of oral peptides, including gastrointestinal tract instability, poor penetrability through intestinal epithelia, and effort in formulation development.

Because of the inherent nature of the gastrointestinal tract, which is not only the prime site of nutrient uptake and food processing but also the first line of defense against infections and toxins. Such physiological barriers are the major impediments to oral absorption of peptides which poses a major challenge to the expansion of the market.

Oral Proteins and Peptides Market: Report Scope

Oral Proteins and Peptides Market: Segmentation

The global oral proteins and peptides market is bifurcated based on drug type, application, and region.

Based on the drug type, the global oral proteins and peptides market is divided into octreotide, insulin, calcitonin, plecanatide, and linaclotide. Among these products, insulin is expected to account for the largest share of the market. Linaclotide was the fastest growing segment in 2021 and is expected to grab a large share of total revenue in the coming years.

By application segment, the global oral proteins and peptides market is divided into hormonal disorders, diabetes, bone diseases, and gastric & digestive disorders. Diabetes was the leading application segment accounting for the largest revenue share in 2021. The outsized share of diabetes segment is primarily accredited to the high acceptance of oral insulin in diabetic population and relative increase in the prevalence of diabetes. The bone disease segment is expected to grow at the highest CAGR during the forecast period.

Recent Developments

• In December 2019, Allergan received FDA approval for a drug, Ubrelvy acute migraine treatment. Ubrelvy is the first oral form of a new family of drugs known as calcitonin gene-related peptide (CGRP) inhibitor to be approved by the FDA to treat a neurological condition.
• In June 2020, Chiasma received FDA approval for Mycapssa (octreotide), for long-term maintenance therapy in patients with acromegaly who have tolerated and responded to lanreotide or octreotide treatment.

Oral Proteins and Peptides Market: Regional Landscape

North America to lead the global market during the forecast period

North America is predicted to account for the largest share in the global oral proteins and peptides market during the forecast period. This is majorly due to an increase in the inclination of people for effective treatments and well-developed healthcare infrastructure. Further, the presence of a significant number of major players in the region, as well as growing consumer awareness of the main benefits of oral proteins and peptides, are expected to fuel the market's growth in the near future.

Furthermore, due to improved consumer knowledge of product advantages and an increasing geriatric population, the United States is likely to contribute considerably to the North American oral proteins and peptides market. Asia Pacific market is predicted to grow rapidly as a result of the rising population and strong private sector and government investment in R&D. Furthermore, the quickly increasing biopharmaceutical industry in the region is expected to fuel the growth of the oral proteins and peptides market throughout the forecast period.

Oral Proteins and Peptides Market: Competitive Landscape

Key players active in the global oral proteins and peptides market are;

• Proxima Concepts Limited (Diabetology Ltd.)
• Allergan plc
• Biocon Limited
• Chiasma, Inc.
• Generex Biotechnology Corp.
• Hovione Limited
• Synergy Pharmaceuticals Inc.
• AstraZeneca plc
• Novo Nordisk A/S
• Tarsa Therapeutics Inc.
• Sanofi S.A.
• F. Hoffmann-La Roche AG
• Synthetic Biologics, Inc.
• Novartis International AG.

The global oral proteins and peptides market is segmented as follows:

By Drug Type

• Octreotide
• Insulin
• Calcitonin
• Plecanatide
• Linaclotide

By Application

• Hormonal Disorders
• Diabetes
• Bone Diseases
• Gastric & Digestive Disorders

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa